TY - JOUR
T1 - Is early-onset cancer an emerging global epidemic? Current evidence and future implications
AU - Ugai, Tomotaka
AU - Sasamoto, Naoko
AU - Lee, Hwa Young
AU - Ando, Mariko
AU - Song, Mingyang
AU - Tamimi, Rulla M.
AU - Kawachi, Ichiro
AU - Campbell, Peter T.
AU - Giovannucci, Edward L.
AU - Weiderpass, Elisabete
AU - Rebbeck, Timothy R.
AU - Ogino, Shuji
N1 - Funding Information:
The work of S.O. is supported in part by the U.S. National Institutes of Health grants (R35 CA197735 and R01 CA248857) and the Cancer Research UK Cancer Grand Challenge Award (6340201/A27140). The work of T.U. is supported by grants from the Prevent Cancer Foundation, Japan Society for the Promotion of Science, and the Mishima Kaiun Memorial Foundation.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/10
Y1 - 2022/10
N2 - Over the past several decades, the incidence of early-onset cancers, often defined as cancers diagnosed in adults <50 years of age, in the breast, colorectum, endometrium, oesophagus, extrahepatic bile duct, gallbladder, head and neck, kidney, liver, bone marrow, pancreas, prostate, stomach and thyroid has increased in multiple countries. Increased use of screening programmes has contributed to this phenomenon to a certain extent, although a genuine increase in the incidence of early-onset forms of several cancer types also seems to have emerged. Evidence suggests an aetiological role of risk factor exposures in early life and young adulthood. Since the mid-20th century, substantial multigenerational changes in the exposome have occurred (including changes in diet, lifestyle, obesity, environment and the microbiome, all of which might interact with genomic and/or genetic susceptibilities). However, the effects of individual exposures remain largely unknown. To study early-life exposures and their implications for multiple cancer types will require prospective cohort studies with dedicated biobanking and data collection technologies. Raising awareness among both the public and health-care professionals will also be critical. In this Review, we describe changes in the incidence of early-onset cancers globally and suggest measures that are likely to reduce the burden of cancers and other chronic non-communicable diseases.
AB - Over the past several decades, the incidence of early-onset cancers, often defined as cancers diagnosed in adults <50 years of age, in the breast, colorectum, endometrium, oesophagus, extrahepatic bile duct, gallbladder, head and neck, kidney, liver, bone marrow, pancreas, prostate, stomach and thyroid has increased in multiple countries. Increased use of screening programmes has contributed to this phenomenon to a certain extent, although a genuine increase in the incidence of early-onset forms of several cancer types also seems to have emerged. Evidence suggests an aetiological role of risk factor exposures in early life and young adulthood. Since the mid-20th century, substantial multigenerational changes in the exposome have occurred (including changes in diet, lifestyle, obesity, environment and the microbiome, all of which might interact with genomic and/or genetic susceptibilities). However, the effects of individual exposures remain largely unknown. To study early-life exposures and their implications for multiple cancer types will require prospective cohort studies with dedicated biobanking and data collection technologies. Raising awareness among both the public and health-care professionals will also be critical. In this Review, we describe changes in the incidence of early-onset cancers globally and suggest measures that are likely to reduce the burden of cancers and other chronic non-communicable diseases.
UR - http://www.scopus.com/inward/record.url?scp=85138018736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138018736&partnerID=8YFLogxK
U2 - 10.1038/s41571-022-00672-8
DO - 10.1038/s41571-022-00672-8
M3 - Review article
C2 - 36068272
AN - SCOPUS:85138018736
SN - 1759-4774
VL - 19
SP - 656
EP - 673
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 10
ER -